Table 2.
Baseline characters for the control group and experimental groups extracted from the selected publications.
| Study | Model | Sex | Age | Treatment Drug Injection | Injected Volume | |
|---|---|---|---|---|---|---|
| ROCK Inhibitor | Control (Disease) | Experimental (Treatment) | ||||
| Yun AD ROCKI 2013 | Ab1–42 | Fasudil | Male | N.R | stereotaxic, left lateral ventricle | 10 mg/kg |
| YU AD ROCKI 2020 | APP/PS1 | Ganoderma lucidum Triterpenoids (ROCKI) | Male | 3 months | gavage | 1.4 g/kg |
| Yu AD ROCKI 2017 | APP/PS1 | Fasudil | N.R | N.R | I.P | 25 mg/kg/day |
| Qing-fang AD ROCKI 2018 | APP/PS1 | Fasudil | N.R | 8 months | I.P | 25 mg/kg/day |
| Min-fang AD ROCKI 2020 | APP/PS1 | Fasudil | N.R | 8 months | N.R | 25 mg/kg/day |
| Manish AD ROCKI 2018 | ICV-STZ | Fasudil | N.R | N.R | I.C.V | 3 mg/kg in 10 μL |
| K.H.Reeta AD ROCKI 2017 | ICV-STZ | Edaravone (ROCKI) | Male | N.R | I.C.V | 10 mg/kg |
| Jogender AD ROCKI 2013 | ICV-STZ | Clitoria ternatea (ROCKI) | Male | N.R | I.C.V | 500 mg/kg |
| Jiezhong Yu AD ROCKI 2018 | APP/PS1 | Fasudil | Male | 8 months | I.C.V | 25 mg/kg/day |
| Ming ROCKI 2018 | BCAO | Y-27632 | Male | N.R | I.P | 10 mg/kg |
| Lin Huan ROCKI 2008 | BCAL | Fasudil | Male | N.R | I.P | 10 mg/kg |
| PDE-5 inhibitor | ||||||
| Cuadrado Cognitive PDE5I 2011 | Tg2576 | Sildenafil | Female | 14–16 months | I.P | 15 mg/kg/day |
| Cuadrado-Tejedor Cognitive PDE5I 2017 | Tg2576 | CM-414 (PDE5i) | Female | 14–16 months | I.P | 40 mg/kg/day |
| Garcia Cognitive PDE5I 2013 | J20 | Sildenafil | Both | 3 months | oral gavage | 15 mg/kg |
| Gulisano Cognitive PDE5I 2018 | APPswe | Vardenafil | Both | 9–10 months | I.P | 0.01 mg/kg |
| Puzzo Cognitive PDE5I 2009 | APP/PS1 | Sildenafil, Tadalafil | Both | 3 months | I.P | 3 mg/kg/day |
| Mohamed Cognitive PDE5I 2021 | ICV-STZ | Tadalafil | Male | 2 months | I.C.V | 20 mg/kg/day |
| Venkat Cognitive PDE5I 2019 | Cholesterol crystal | Sildenafil | Male | 16–18 months | Internal carotid artery | 2 mg/kg/day |
| Zhang Cognitive PDE5I 2018 | Multiple micro infarction | KJH-1002 (PDE5i) | Male | 9 weeks | gavage | 20 mg/kg |
| Zhu Cognitive PDE5I 2015 | APP/PS1 | Sildenafil | Male | 7 months | I.P | 6 mg/kg |
| Bhatia Cognitive PDE5I 2019 | BCAO | Tadalafil | Both | 8–9 weeks | oral | 10 mg/kg |
| Gulati Cognitive PDE5I 2014 | BCAO | Tadalafil | Male | N. R | N. R | 20 mg/kg |
| Gulati P Cognitive PDE5I 2014 | BCAO | Tadalafil | Male | N. R | N. R | 20 mg/kg |
BCAO: bilateral carotid artery ligation, ICV: intracerebral vascular, ICV-STZ: intracerebral vascular -streptozotocin, I.P: intraperitoneal, N.R: no record, PDE5I: phosphodiesterase 5 inhibitor, PS1: presenilin 1, ROCKI: rho-associated kinase inhibitor.